Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.70), $0.03 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $45.9 million versus the consensus estimate of $47.75 million.

For the full year of 2025, the Company expects total research and development plus selling, general and administrative expenses to be $380 to $385 million, compared to prior guidance of $370 to $390 million, both estimates excluding an estimated $45 million in non-cash stock compensation expense.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.